Commack: 
Genentech Lucerne Study
Now enrolling for Neovascular Age-Related Macular Degeneration
This is a new drug called faricimab that may allow us to dose less frequently for wet AM
HAWK Study
About this Study
The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye.
CEDAR Study
About this Study
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration.
New Treatment for Neovascular Age-Related Macular Degeneration
Enrollment is Open
About this Study
This is a phase 3 study using Combercept which is a long- acting antiVEGF agent.
It is hoped that with this drug, patients will require fewer eye injections.
Genentech Yosemite Study
New Treatment for Diabetic Macular Edema
Enrollment is Open
About this Study
This is a phase 3 study looking at a new drug RO6867461. It has the potential to improve vision with fewer eye injections.
Graybug Vision
New Treatment for Neovascular Age-related Macular Degeneration
Enrollment is Open
About this Study
This is a phase 2 study looking at a long release anti-VEGF which may require injections as infrequently as every 6 months.
